Say it isn’t pso: IL-25 drives skin inflammation

See allHide authors and affiliations

Science Immunology  04 May 2018:
Vol. 3, Issue 23, eaat9662
DOI: 10.1126/sciimmunol.aat9662

eLetters is an online forum for ongoing peer review. Submission of eLetters are open to all. eLetters are not edited, proofread, or indexed.  Please read our Terms of Service before submitting your own eLetter.

Compose eLetter

Plain text

  • Plain text
    No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.
Author Information
First or given name, e.g. 'Peter'.
Your last, or family, name, e.g. 'MacMoody'.
Your email address, e.g. higgs-boson@gmail.com
Your role and/or occupation, e.g. 'Orthopedic Surgeon'.
Your organization or institution (if applicable), e.g. 'Royal Free Hospital'.
Statement of Competing Interests

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

Vertical Tabs

  • IL-25 drives skin inflammation in psoriasis - the potential for clinical utility of IL-25 as a therapeutic target
    • Dr Dianne Sika-Paotonu, Associate Dean (Pacific)/Senior Lecturer Pathology & Molecular Medicine, Wellington School of Medicine & Health Sciences, University of Otago, New Zealand

    To the Editor,

    I read with interest the report prepared by Kalekbar, L.A., & Rosenblum, M.D., (1) and entitled: “Say it isn’t pso: IL-25 drives skin inflammation.” This commentary was based on work by Xu. et al (2) entitled: “An Interleukin-25-Mediated Autoregulatory Circuit in Keratinocytes Plays a Pivotal Role in Psoriatic Skin Inflammation.”

    Some of the key points highlighted were that IL-25 otherwise known as IL-17E and a cytokine belonging to the IL-17 family, is highly expressed in psoriasis (in humans and mice) and that intradermal IL-25 causes psoriasis-like disease in mice.

    In addition, IL-25 derived from keratinocytes was shown as being needed for the development of psoriasis-like disease and skin inflammation with treatment with anti-IL-25 able to improve disease. Collectively these results indicate that IL-17A expression during early psoriasis development triggers IL-25 expression and release from keratinocytes which acts in an autocrine manner and promotes keratinocyte proliferation, inducing pro-inflammatory responses via cytokines and chemokines mediated by STAT3 transcription factor activation.

    Although further work will be required, the potential clinical application of these findings remains promising. Psoriasis is a chronic inflammatory skin disease that continues to cause significant distress and discomfort to those suffering from the condition and the potential for clinical utility of IL-25 as a therapeutic target war...

    Show More
    Competing Interests: None declared.

Stay Connected to Science Immunology

Navigate This Article